{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.84","upperLimit":"0.92","value":"0.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"}],"units":"Participants"}],"description":"Survival is defined as the minimum time from study entry to a relapse of higher risk at any time, any relapse following treatment with protocol mandated IFRT, death from any cause, or the occurrence of a second malignant neoplasm. This will be used to compute intensive therapy free survival (ITFS). Patients without report of such events where censored at last contact. This differs from traditional EFS in that relapse after AVPC\\* x3 therapy alone that does not place the patient in a higher risk category is not considered a treatment failure. In this definition, higher-risk relapse refers to relapse involving sites and extent of disease that place the patient in the current COG definition of intermediate or high-risk disease. If a patient with CR who experiences a LR relapse is not retreated with protocol-mandated chemotherapy and IFRT, subsequent disease relapses will nevertheless be counted in the analysis of the treatment strategy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim","id":"OG000","title":"Group 1"}],"paramType":"NUMBER","populationDescription":"Eligible (n=278) and evaluable response and review of response, n=275. Follow-up for censored patients (n=245) is 76 months (range: 4.7 to 109 months).","reportingStatus":"POSTED","timeFrame":"At 60 months","title":"Intensive Therapy Free Survival (ITFS).","type":"PRIMARY","unitOfMeasure":"Probability of survival"}